Dr Fathima Shehnaz Ayoobkhan speaks to ecancer about the oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma.

Multiple Myeloma affects nearly half a million people annually and is currently incurable, though treatments can prolong life.

MRD testing is vital for evaluating treatment success and patient outcomes.

A global study reveals that 42% of US oncologists endorse MRD testing, compared to only 28% internationally.

Challenges such as cost and availability hinder its use, highlighting the need for standardised guidelines to enhance cancer care access worldwide.